Michelle Sholzberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michelle Sholzberg has a total of 514 co-authors. Here are the top co-authors by number of shared publications:
Grace H. Tang
Hematology-Oncology Clinical Research Group, St. Michael’s Hospital, Toronto, Ontario, Canada
10 shared publicationsJerome Teitel
Division of Hematology/Oncology, St. Michael’s Hospital, Toronto, Canada
9 shared publicationsGeorgina Floros
Division of Hematology/Oncology, St. Michael’s Hospital, Toronto, Canada
8 shared publicationsRosane Nisenbaum
Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada; MAP Centre for Urban Health Solutions, Toronto, Ontario, Canada; Applied Health Research Centre, Toronto, Ontario, Canada; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
8 shared publicationsMichael Fralick
General Internal Medicine, Sinai Health, University of Toronto, Toronto, ON, Canada
7 shared publications- Alfonso Iorio
Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada
6 shared publications
Latest Publications
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7353-7374
American Society of Hematology 2026 guidelines for diagnosis of iron deficiency
Background: Iron deficiency is the most common micronutrient deficiency and, when untreated, progresses to anemia. Existing guidance on the diagnostic criteria for iron deficiency is limited and not evidence based. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the diagnosis of iron deficiency, taking a global perspective in all settings. Methods: ASH established a multidisciplinary guideline panel that included 1 patient representative and was balanced to minimize potential bias from conflicts of interest. The University of Kansas Health System supported the guideline-development process, including performing systematic evidence reviews on the prevalence of iron deficiency across populations and studies to inform diagnostic thresholds up to July 2025. The panel prioritized clinical questions according to clinical impact and high-risk populations. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently open for public comment. Results: The panel agreed on 5 recommendations. Conclusions: Key recommendations of these guidelines include serum ferritin thresholds for specific populations, with the goal to prioritize the diagnosis of iron deficiency, irrespective of the presence of anemia, remarks for considerations of other diagnostic thresholds, and guidance on the diagnosis of iron deficiency in persons with inflammation. Gaps in the literature and research priorities were also identified.
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7353-7374
American Society of Hematology 2026 guidelines for diagnosis of iron deficiency
Background: Iron deficiency is the most common micronutrient deficiency and, when untreated, progresses to anemia. Existing guidance on the diagnostic criteria for iron deficiency is limited and not evidence based. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the diagnosis of iron deficiency, taking a global perspective in all settings. Methods: ASH established a multidisciplinary guideline panel that included 1 patient representative and was balanced to minimize potential bias from conflicts of interest. The University of Kansas Health System supported the guideline-development process, including performing systematic evidence reviews on the prevalence of iron deficiency across populations and studies to inform diagnostic thresholds up to July 2025. The panel prioritized clinical questions according to clinical impact and high-risk populations. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently open for public comment. Results: The panel agreed on 5 recommendations. Conclusions: Key recommendations of these guidelines include serum ferritin thresholds for specific populations, with the goal to prioritize the diagnosis of iron deficiency, irrespective of the presence of anemia, remarks for considerations of other diagnostic thresholds, and guidance on the diagnosis of iron deficiency in persons with inflammation. Gaps in the literature and research priorities were also identified.
- Open Access
heaterBack to work MD - Experiences of internal medicine physicians returning to work after parental leave
Background: Parenthood in medicine is an experience fraught with challenges that begin in the pre-conception phase and persist as physician-parents navigate their dual role. Methods: This study aims to understand the experiences of physician-parents (both childbearing and non-childbearing) returning to work after parental leave. Physicians, including residents, affiliated with the University of Toronto’s Department of Medicine internal medicine division who had a child within the last ten years were invited to participate in a self-administered electronic survey from June2022 to 30June 2023. Data were summarized using descriptive statistics. Results: Twenty-nine respondents took part in the survey; 79% were staff physicians while the remaining were trainees at the time of the survey. At the time their first child was born, 48% were staff members and 52% were trainees. The median duration of parental leave was 5 months (range 1-12 months). Among those for whom lactation was applicable, 76% reported that they continued their lactation efforts on returning to work, while 24% chose not to. Thirty five percent (35%, n =6/17) of respondents cited that they were not provided with duty hour modifications when required. Many respondents (46%) felt guilty about burdening their co-workers for requesting accommodations for childcare. When requested to rate their experiences of balancing their personal and professional lives on a scale of 1-10 (1 being “impossible to maintain” and 10 being “extremely easy to maintain”), most respondents (66%) chose a rating of 5 or less. Conclusion: This study supports previous findings that physician-parents face a myriad of challenges integrating their roles in medicine and parenthood. A change in culture is required to support and normalize parenthood for physicians and foster sustainability and productivity in academic medicine.
Open AccessheaterBack to work MD - Experiences of internal medicine physicians returning to work after parental leave
Background: Parenthood in medicine is an experience fraught with challenges that begin in the pre-conception phase and persist as physician-parents navigate their dual role. Methods: This study aims to understand the experiences of physician-parents (both childbearing and non-childbearing) returning to work after parental leave. Physicians, including residents, affiliated with the University of Toronto’s Department of Medicine internal medicine division who had a child within the last ten years were invited to participate in a self-administered electronic survey from June2022 to 30June 2023. Data were summarized using descriptive statistics. Results: Twenty-nine respondents took part in the survey; 79% were staff physicians while the remaining were trainees at the time of the survey. At the time their first child was born, 48% were staff members and 52% were trainees. The median duration of parental leave was 5 months (range 1-12 months). Among those for whom lactation was applicable, 76% reported that they continued their lactation efforts on returning to work, while 24% chose not to. Thirty five percent (35%, n =6/17) of respondents cited that they were not provided with duty hour modifications when required. Many respondents (46%) felt guilty about burdening their co-workers for requesting accommodations for childcare. When requested to rate their experiences of balancing their personal and professional lives on a scale of 1-10 (1 being “impossible to maintain” and 10 being “extremely easy to maintain”), most respondents (66%) chose a rating of 5 or less. Conclusion: This study supports previous findings that physician-parents face a myriad of challenges integrating their roles in medicine and parenthood. A change in culture is required to support and normalize parenthood for physicians and foster sustainability and productivity in academic medicine.
- 14 May 2026
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 48 (8) , 103395
Maternal Non-Anemic Iron Deficiency in Early Pregnancy and Infant Neurodevelopment: A Critical Appraisal
- 14 May 2026
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 48 (8) , 103395
Maternal Non-Anemic Iron Deficiency in Early Pregnancy and Infant Neurodevelopment: A Critical Appraisal
- 4 March 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (5) , 1627-1642
Assessing preoperative bleeding risk using international normalized ratio and activated partial thromboplastin time: a systematic review
- 4 March 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (5) , 1627-1642
Assessing preoperative bleeding risk using international normalized ratio and activated partial thromboplastin time: a systematic review
- Open Access
- 23 October 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (8)
Multidisciplinary perinatal care for women with bleeding disorders
- 23 October 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (8)
Open AccessMultidisciplinary perinatal care for women with bleeding disorders
- Open Access
- 12 September 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (5) , 2219-2223
‘Raise the Bar’, a Canadian intervention to combat disparities in the recognition and management of iron deficiency: Development of the intervention, feasibility and implementation
- 12 September 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (5) , 2219-2223
Open Access‘Raise the Bar’, a Canadian intervention to combat disparities in the recognition and management of iron deficiency: Development of the intervention, feasibility and implementation
- Open Access
- 10 August 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (27) , E819-E827
Diagnostic et prise en charge de la carence en fer chez les femmes
- 10 August 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (27) , E819-E827
Open AccessDiagnostic et prise en charge de la carence en fer chez les femmes
- Top Cited PapersOpen Access
- 1 July 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (24) , E680-E687
Diagnosis and management of iron deficiency in females
- 1 July 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (24) , E680-E687
Top Cited PapersOpen AccessDiagnosis and management of iron deficiency in females
- Open Access
- 22 January 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (3) , 439-449
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count < 30 × 109/L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017–004012‐19). Oral rilzabrutinib 400 mg bid was given over 24 weeks, with optional long‐term extension (LTE). Primary endpoints were safety and platelet counts ≥ 50 × 109/L on ≥ 8 of the last 12 weeks of main treatment without rescue medication. From 22 March2018 to 31 January2023, 26 patients were enrolled. Patients had baseline median platelet count 13 × 109/L, ITP duration 10.3 years, and six prior ITP therapies (46% splenectomized). Nine (35%) patients achieved the primary endpoint. Platelet counts ≥ 50 × 109/L or ≥ 30 × 109/L and doubling from baseline without rescue therapy were sustained for a mean 9.3 weeks. 11 (42%) LTE‐eligible patients were ongoing with median LTE platelet > 80 × 109/L. Three (12%) patients received rescue medication during main treatment, none in LTE. Clinically meaningful improvements were observed in fatigue and women's health. With a median treatment duration of 167 days (main treatment), 16 (62%) patients had ≥ 1 treatment‐related adverse event (AE), mainly grade 1, including diarrhea (35%), headache (23%), and nausea (15%). There was no treatment‐related grade ≥ 2 bleeding/thrombotic events/infections, serious AE, or death. Rilzabrutinib continues to demonstrate durable platelet responses with favorable safety profile in previously treated ITP patients. Trial Registration: NCT03395210, EudraCT 2017‐004012‐19
- 22 January 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (3) , 439-449
Open AccessEfficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count < 30 × 109/L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017–004012‐19). Oral rilzabrutinib 400 mg bid was given over 24 weeks, with optional long‐term extension (LTE). Primary endpoints were safety and platelet counts ≥ 50 × 109/L on ≥ 8 of the last 12 weeks of main treatment without rescue medication. From 22 March2018 to 31 January2023, 26 patients were enrolled. Patients had baseline median platelet count 13 × 109/L, ITP duration 10.3 years, and six prior ITP therapies (46% splenectomized). Nine (35%) patients achieved the primary endpoint. Platelet counts ≥ 50 × 109/L or ≥ 30 × 109/L and doubling from baseline without rescue therapy were sustained for a mean 9.3 weeks. 11 (42%) LTE‐eligible patients were ongoing with median LTE platelet > 80 × 109/L. Three (12%) patients received rescue medication during main treatment, none in LTE. Clinically meaningful improvements were observed in fatigue and women's health. With a median treatment duration of 167 days (main treatment), 16 (62%) patients had ≥ 1 treatment‐related adverse event (AE), mainly grade 1, including diarrhea (35%), headache (23%), and nausea (15%). There was no treatment‐related grade ≥ 2 bleeding/thrombotic events/infections, serious AE, or death. Rilzabrutinib continues to demonstrate durable platelet responses with favorable safety profile in previously treated ITP patients. Trial Registration: NCT03395210, EudraCT 2017‐004012‐19